Journal of Cellular Physiology

Cover image for Vol. 230 Issue 9

Edited By: Gary S. Stein, Harvey M. Florman and Constance E. Brinckerhoff

Impact Factor: 3.874

ISI Journal Citation Reports © Ranking: 2013: 14/81 (Physiology); 77/185 (Cell Biology)

Online ISSN: 1097-4652

Recently Published Issues

See all

Top Cited Articles 2014

Franchina, T., Amodeo, V., Bronte, G., Savio, G., Ricciardi, G. R.R., Picciotto, M., Russo, A., Giordano, A. and Adamo, V.
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer
Journal of Cellular Physiology 2014, vol. 229, p. 97

Basile, D. P. and Yoder, M. C.
Circulating and Tissue Resident Endothelial Progenitor Cells
Journal of Cellular Physiology 2014, vol. 229, p. 10

Anderson, M., Roshanravan, H., Khine, J. and Dryer, S. E.
Angiotensin II Activation of TRPC6 Channels in Rat Podocytes Requires Generation of Reactive Oxygen Species
Journal of Cellular Physiology 2014, vol. 229, p. 434

Zhang, Y.-Y., Yue, J., Che, H., Sun, H.-Y., Tse, H.-F. and Li, G.-R
BKCa and hEag1 Channels Regulate Cell Proliferation and Differentiation in Human Bone Marrow-Derived Mesenchymal Stem Cells
Journal of Cellular Physiology 2014, vol. 229, p. 202

Basile, D. P. and Yoder, M. C.
Circulating and Tissue Resident Endothelial Progenitor Cells
Journal of Cellular Physiology 2014, vol. 229, p. 10

See More Here

SEO Tips for Authors

SEO Author

JCP Spotlight Article

Melanoma Treatments: Advances and Mechanisms

Alexander Marzuka, Laura Huang, Nicholas Theodosakis and Marcus Bosenberg

Advances in the understanding of the molecular pathogenesis of melanoma and in cancer immunology have led to the rational design and recent clinical implementation of a variety of novel therapies for metastatic melanoma. BRAF and MEK inhibitors that target the MAPK pathway have high rates of clinical response in BRAF-mutant melanoma. Therapies that modulate the immune response to melanoma, including monoclonal antibodies that interfere with pathways that inhibit T-cell function, have been shown to be effective in melanoma. Lessons learned from these encouraging results are driving the development of new treatments for melanoma and other cancers. This review will focus on the science and clinical findings related to targeted therapies that inhibit BRAF or MEK as well as the immunotherapies that block the CTLA-4 or PD-1 pathways. Other experimental and combinatorial therapeutic approaches will also be discussed.

Freely Available for A Limited Time

Read

PHYSIOLOGY EcThis content will be freely available to all through September 17th. Don't miss out.

New Content

Subscribe to RSS headline updates from: Journal of Cellular Physiology
Powered by FeedBurner

SEARCH

SEARCH BY CITATION